Researchers examined whether CDK4/6 inhibitors lead to better overall survival when used as first- or second-line treatment.
The NDA is based on results from the Phase III evERA Breast Cancer study. Credit: NMK-Studio / Shutterstock.com. (NMK-Studio / Shutterstock.com.) Roche has obtained acceptance from the US Food and ...
The FDA application is supported by data from the Phase 3 evERA Breast Cancer study. The trial results showed that the combination of giredestrant and Afinitor reduced the risk of disease progression ...
Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that Itovebi® (inavolisib) is the first breast cancer therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results